Through our ongoing work with the American Optometric Association (AOA) and the American Dental Association (ADA), Avalon has recently conducted survey research to update our 2016 “Analysis of Dental and Vision Plan Non-Covered Services and Materials Mandates.”
In 2016, we conducted a survey-based study of optometry and dentistry in North Carolina and Texas to determine the impact on fees charged in states with laws prohibiting insurers from setting fees for non-covered services.
Focusing only on cases and deaths hides the pandemic’s lasting health burden on people, societies and economies. The COVID-19 pandemic is well into its second year, but countries are only beginning to grapple with the lasting health crisis.
Chronic kidney disease (CKD) is a costly public health issue, which affects 13.4% of the population globally.
Together with our colleagues at Broadstreet Health Economics and Outcomes Research, Avalon’s John Schneider took part in an ISPOR workshop entitled “Lost in Transmission: Analytic Applications of Public Health Data to Inform Evaluations of the Efficacy, Effectiveness, and Value of Interventions for COVID-19.”
John Schneider and Amanda Howarth collaborated with Broadstreet Health Economics and Outcomes Research on a poster entitled “Leveraging Publicly Available Data to Estimate a Real-Time Reproduction Number (Rt) for Covid-19- A Comparison of Two Methods”.
The Avalon team employed Mendelian randomization to help Novartis understand the proportion of obesity costs that might be explained by genetic causes.
Tobacco product waste (TPW) is one of the most ubiquitous forms of litter, accumulating in large amounts on streets, highways, sidewalks, beaches, parks, and other public places, and flowing into storm water drains, waste treatment plants, and solid waste collection facilities.
In many ways the arrival of the COVID-19 pandemic globally was met with sub-optimal levels of preparedness on the part of health care providers and provider systems, such as integrated delivery networks (IDNs).
This blog covers the presentation given as part of the ISPOR pre-conference plenary session on HEOR in the era of COVID-19 which was held on 14 May 2020.
The Wall Street Journal recently covered the work that Avalon’s Andrew Briggs conducted on the excess mortality attributable to COVID-19. Briggs put the U.S. average at almost 14 years lost and the U.K. average at almost 11 years.
The Avalon team helped Inflammatix, Inc., develop economic evidence for HostDx Sepsis test for the diagnosis of acute infections. A newly released publication describes a cost impact model comparing the cost of standard of care versus the use of HostDx Sepsis in two hypothetical arms with 1000 patients presenting with symptoms of ARTI in the…
In this blog entry we explore some of the potentially important issues surrounding the role of EMRs in litigation, where the discovery of medical documents and records increasing involves digitally stored data.[1-4]
Avalon Director Andrew Briggs, DPhil, addresses the issue of potential losses in quality-adjusted life years (QALYs) associated with COVID-19.
We define epidemiology broadly, including an up-to-date review of the key published medical literature on COVID-19. Following that, our discussion of costs focuses in part on the direct medical costs (which probably for good reasons has been relatively under-reported) and in part on the broader costs to the economy.
Avalon researchers published important research on distinguishing between viral and bacterial respiratory infections, a topic that is of great importance given the COVID-19 pandemic. Check out the study at: https://www.tandfonline.com/doi/full/10.1080/13696998.2020.1736872 TweetSharePinShare0 Shares
By: The Avalon Health Economics Team March 13, 2020 Within a few months we’ve gone from worrying about holiday shopping to worrying about global pandemics and watching the world shut down around us. It started with news from China on the rapid spread of an insidious virus initially called a coronavirus.[1] Once the virus was…
Avalon Health Economics will be at ISPOR Copenhagen November 2nd-6th. Let us know if you will be there and want to set up a meeting! For more information, please visit the ISPOR website.
Economic evaluation of passive monitoring technology for seniors 2019 By John E. Schneider, Jacie Cooper. Cara Scheibling, and Anjani Parikh Abstract: By 2050, the global population of persons over the age of 60 is expected to be between 1.5 and 2 billion [1, 2]. Moreover, the proportion of individuals over the age of 80 is simultaneously and…
Avalon Health Economics has entered into a collaborative agreement with Oberender, a leading global healthcare management consultancy based in Germany. The agreement allows Avalon and Oberender to collaborate in a variety of ways, offering Avalon’s U.S. clients access to European market access, technology assessment, and management consulting, and offering Oberender added reach into…
This research summary is written by John E. Schneider, PhD & Cara M. Scheibling A two-decade drumbeat of bold, future-focused and entirely bi-partisan changes in U.S. state laws has ushered in the modern practice of optometry. The result has been a dramatic expansion of the profession’s independent physician role in health care coupled with…
Avalon Health Economics will be at ISPOR New Orleans, May 18 through May 22. We will be engaged in our usual array of posters, podium presentations, and short courses. If you are planning on attending, please let us know if you want to meet with any of our team! TweetSharePinShare0 Shares
Avalon Health Economics is happy to announce an exciting new collaboration with the London-based Acaster-Lloyd Consulting, Ltd. Acaster-Lloyd, led by Sarah Acaster and Andrew Lloyd, is a leader in the area of clinical outcomes assessment (COA), including patient-reported outcomes, health-state utilities, strategy & analysis, preference surveys, instrument development, and qualitative research. The collaboration helps AHE…
Avalon Health Economics will be at ISPOR Barcelona, Nov. 10 through Nov. 14. We will be engaged in our usual array of posters, podium presentations, and short courses. If you are planning on attending, please let us know if you want to meet with any of our team! TweetSharePinShare0 Shares
Avalon will be attending AdvaMed in Philadelphia this September 24th-26th. To schedule meetings with the Avalon team, contact Nicole Nelson at nicole.nelson@avalonecon.com. TweetSharePinShare0 Shares
AHE Presents: Symposium on Emerging Trends in U.S. Health Economic Evaluation: A Closer Look at the Role of Cost Effectiveness in U.S. Market Access, Tuesday May 9th in Morristown, NJ TweetSharePinShare0 Shares
CEO John Schneider will be speaking at Research! America’s Medical Innovation 101 February briefing on Capitol Hill with Dr. Keith R. Yamamoto, Director of Precision Medicine at the University of California San Francisco, Dr. Joe V. Selby, Executive Director at PCORI, and others. TweetSharePinShare0 Shares
John Schneider & Andrew Briggs will be teaching the Economics of Diagnostics Introduction Course on Sunday afternoon (1:00pm-5:00pm). Come say hi or sign up for the course! Let us know if you would like to schedule a time to meet in Vienna. TweetSharePinShare0 Shares
Our research found that for doctors of optometry and dentists in both states, even after the enactment of laws barring NCS mandates, the vast majority of providers continued to offer normal discounts and receive payments from patients that were below their charged amounts. Thus, the laws had no effect on the providers—they continued billing their…
Avalon CEO John Schneider, Ph.D. presented at BMO Capital Markets’ “The Year Ahead in Healthcare: Products, Payment and Politics” on December 15, 2015. The day-long symposium was focused on markets for life science products and featured presentations from industry leaders, including Boston Scientific, Medtronic, Abbott and Pfizer. Schneider delivered a lunchtime presentation on the medical…
Avalon Health Economics is happy to announce the addition of Philipp Schuetz, MD, MPH as our Clinical Advisor. He is a board-certified internist and endocrinologist. He has broad clinical and research interests focusing on the application of new developments in endocrinology, infectious diseases, critical illness and general medicine. He has done extensive research on hormones,…
CEO John Schneider presented at the Barclays HealthCare Symposium on 11/20 on the topic of Increasing Need to Demonstrate Economic Value in Medtech. TweetSharePinShare0 Shares
The annual AdvaMed Med Tech Conference is the leading MedTech Conference in North America, bringing more than 1,000 companies together to exchange knowledge and ideas on business development, capital formation, economic evaluation, pricing and reimbursement, educational opportunities and networking. Please let us know if you like to meet and discuss your health economics needs. To…
Avalon Health Economics will be presenting in several venues at the 18th Annual European Congress of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) in Milan, 7-11 November 2015 at the Milano Congressi (MiCo ). The Avalon presentations include: (1) teaching the first ISPOR short course on the Economics of Diagnostics; (2) moderating an…
Avalon at ISPOR: John Schneider, Cara Scheibling, and Ivana Stojanovic will be attending the annual meeting of the International Society of Pharmacoeconomics and Outcomes Research in Philadelphia this week, May 16 through May 20. The title of this year’s meeting is “Integrating Big Data, Patient Data, and Cost-Effectiveness into Clinical Practice: Promise and Prospects.” If…
Avalon CEO John Schneider presents on “The Economics of Molecular Diagnostics” at the University of California Berkeley’s School of Public Health. The lecture covered the basics of molecular diagnostics followed by a more detailed assessment of the costs and benefits of molecular diagnostics. Discussions centered around the value of diagnostics, and how payers and patients…
The demand for medical care services in the U.S. has long been the envy of other industries. Americans are generally not accustomed to going without, typically despise most non-market forms of rationing, and don’t like government telling them what they can and can’t have. Beneath this culture of consumption lie several layers of public and…
Avalon team publishes study of the U.S. cost impact of procalcitonin testing in acute respiratory infections. In the inpatient setting, the costs of procalcitonin guided compared to usual care for the one million member cohort was $ 2,083,545, compared to $ 2,780,322, resulting in net savings of nearly $ 700,000 to the IDN for 2014….
John Rizzo, PhD, joins Avalon Health Economics as a Consultant. In addition to his role as Consultant with Avalon Health Economics, Dr. Rizzo is Professor of Economics and Preventive Medicine at Stony Brook University (NY) and Chief Economist at the Long Island Association. His research interests include applied economic studies of health care markets and…
CEO John Schneider presented at Nordic Life Science Days in Stockholm, Sweden on the Economic Evaluation of pharmaceutical drugs, medical devices, and diagnostics. Nordic Life Science Days attracts leading decision makers from the Life Science sector, not only from biotech, pharma and medtech but also from finances, research, policy and regulatory authorities. Click here to…
Ivana Stojanovic, MA, has joined Avalon Health Economics as a Health Economist. Ivana has several years of experience in economics consulting, and has expertise in conducting data analysis and research for litigation support. Her quantitative skills include SAS, SQL, STATA, and Basic VBA. Click here for Ivana’s full biosketch. TweetSharePinShare0 Shares
Avalon Health Economics will be attending Nordic Life Science Days 2014, Stockholm, Sweden, September 7-9. Avalon will present “Establishing the Value of New Drugs, Devices & Diagnostics” (See Presentation). The NLSD is the largest life sciences meeting held in the Nordic region, and will include representatives from pharmaceutical companies, medical device makers, diagnostics companies, and…
Noemi Kiss is a Senior Health Economist with Avalon. She recently earned her MSc in Health Economics from the University of York (United Kingdom). Prior to York, Ms. Kiss was a Health Economist at Oxford Outcomes, Ltd (and Oxford’s parent company ICON plc), from 2010-13. Click here to read her biosketch. In addition to her…
James Robinson joins Avalon Health Economics as a Director. Jamie is the Leonard D. Schaeffer Professor of Health Economics and Director of the Berkeley Center for Health Technology (BCHT) at the University of California at Berkeley. In addition to his role as Director at Avalon Health Economics, his professional activities include his roles as Senior…
Click here to view the presentation TweetSharePinShare0 Shares
Avalon at ISPOR: John Schneider and Cara Scheibling will be attending the annual meeting of the International Society of Pharmacoeconomics and Outcomes Research in Montreal next week, June 1 through June 4. The title of this year’s meeting is “Examining the Role of Big Data in Health Care Decision Making.” If you’d like to meet,…
Avalon will be attending and presenting at the 6th Annual EuroMedtech conference in Linz, Austria, May 7-8. The topic will be on economic evaluation of devices and diagnostics through the product lifecycle. Economic evaluations of new devices and diagnostics should begin early, and should be adjusted and revised throughout the product lifecycle as better data…
Conjunctivitis is a common condition of the eye that occurs worldwide and affects all ages and social strata, affecting more than 2 percent of the population. It is caused by a variety of bacterial or viral pathogens but may also be caused by allergies, irritants or medications. Most types are self-limiting, but some may progress…
Michael J. Lacey, MSc, has joined Avalon Health Economics as a Senior Consultant focusing on Economic Modelling & Value Strategy. He also works as an independent health economics consultant. He has over 15 years industry experience leading new product market access, health economics and pricing strategy development within medical technology firms. He was Senior Director…
Joining us recently is Megan Modic, who will provide research assistance on a variety of projects. Ms. Modic is currently earning her Bachelor’s degree in Honors Economics and Environmental Science at Drew University, in Madison, NJ, where she is President of The Fund, a student run investment portfolio. TweetSharePinShare0 Shares
Avalon CEO John Schneider spoke at the 6th Annual Latin American & Canada Clinical Laboratory Symposium, Cartagena, Columbia, October 16th and 17th. The title of his talk was “Economics of Cancer Biomarkers: Cost Effectiveness of HE4 in Clinical Decision Making Dr. Schneider’s presentation focused on a conceptual framework for exploring the economic aspects of cancer…
Avalon Health Economics CEO John Schneider presented at the Truck Safety and Litigation Seminar hosted by Marcello & Kivisto LLC law firm in April 2013. In his presentation Dr. Schneider spoke about motor carrier liability cases involving large medical losses, and how Avalon Health Economics uses a common health economics methodology to calculate the “reasonable…
Avalon Health Economics is happy to announce the addition of two new consultants to our panel. Jeff Kamil, MD, joins us in the area of U.S. market access and reimbursement. Jeff worked with John Schneider, Avalon’s CEO, several years ago when John was Director of Research at the California Association of Health Plans. Dr. Kamil…
TweetSharePinShare0 Shares
